Várvölgyi Tünde, Janka Eszter Anna, Szász István, Koroknai Viktória, Toka-Farkas Tünde, Szabó Imre Lőrinc, Ványai Beatrix, Szegedi Andrea, Emri Gabriella, Balázs Margit
Department of Dermatology, MTA Centre of Excellence, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
HUN-REN-UD Allergology Research Group, University of Debrecen, 4032 Debrecen, Hungary.
J Clin Med. 2023 Dec 28;13(1):174. doi: 10.3390/jcm13010174.
The early detection of melanoma relapse can improve patient survival; thus, there is a great need for easily accessible biomarkers that facilitate the diagnosis of metastatic disease. We investigated the diagnostic effect of blood biomarkers such as lactate dehydrogenase (LDH), S100B, and osteopontin in the detection of metastases. Clinical data and peripheral blood samples of 206 melanoma patients were collected (no metastasis, N = 120; metastasis, N = 86). The discriminative power of blood biomarkers, patient demographics, and clinicopathological parameters of primary melanomas were evaluated using univariate and multivariate logistic regression models and receiver operating characteristic (ROC) analysis to determine the area under the curve (AUC). Plasma osteopontin levels showed a significant and independent effect on the probability of metastasis, similar to serum S100B levels. In addition, the location of the primary tumor on the lower extremities and the American Joint Committee on Cancer (AJCC) categories pT2b-3a, pT3b-4a, and pT4b were associated with the diagnosis of metastasis. Importantly, the combination of the three blood biomarkers and primary tumor localization and AJCC pT category yielded excellent discrimination (AUC: training set: 0.803; validation set: 0.822). In conclusion, plasma osteopontin can be classified as a melanoma biomarker; moreover, by combining clinicopathological prognostic variables, the diagnostic effect of blood biomarkers in the detection of metastatic melanoma can be improved.
黑色素瘤复发的早期检测可提高患者生存率；因此，迫切需要易于获取的生物标志物以促进转移性疾病的诊断。我们研究了乳酸脱氢酶（LDH）、S100B和骨桥蛋白等血液生物标志物在转移检测中的诊断效果。收集了206例黑色素瘤患者的临床数据和外周血样本（无转移，N = 120；有转移，N = 86）。使用单变量和多变量逻辑回归模型以及受试者工作特征（ROC）分析来评估血液生物标志物、患者人口统计学特征和原发性黑色素瘤的临床病理参数的判别能力，以确定曲线下面积（AUC）。血浆骨桥蛋白水平对转移概率显示出显著且独立的影响，与血清S100B水平相似。此外，原发性肿瘤位于下肢以及美国癌症联合委员会（AJCC）分类中的pT2b - 3a、pT3b - 4a和pT4b与转移诊断相关。重要的是，三种血液生物标志物与原发性肿瘤定位和AJCC pT分类的组合产生了出色的判别能力（AUC：训练集：0.803；验证集：0.822）。总之，血浆骨桥蛋白可被归类为黑色素瘤生物标志物；此外，通过结合临床病理预后变量，可提高血液生物标志物在转移性黑色素瘤检测中的诊断效果。
